Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

TG Therapeutics Short Interest Declines Indicating Potential Shift in Market Sentiment

Elaine Mendonca by Elaine Mendonca
January 19, 2024
in Breaking News
0
0
SHARES
14
VIEWS
Share on FacebookShare on Twitter

TG Therapeutics (NYSE:TGTX) has experienced a notable decline in its short interest, with the percentage of float falling by 12.86% since the previous report. As of January 19, 2024, the company reported 31.83 million shares sold short, which accounts for 25.88% of all regular shares available for trading. This suggests that traders are exhibiting less bearishness towards the stock. The current short interest ratio stands at 5.0, indicating a moderate level of pessimism.

Understanding short interest is crucial as it provides insights into market sentiment surrounding a specific stock. An increase in short interest typically signifies bearishness, while a decrease can indicate bullishness. Nevertheless, it is important to note that a decline in short interest does not guarantee an immediate rise in the stock’s value.

When comparing TG Therapeutics’s short interest to its peers, the company’s average short interest as a percentage of float is reported to be 15.13% by Benzinga Pro.

In conclusion, the decrease in TG Therapeutics’s short interest may suggest a shift in market sentiment towards the stock. However, it is crucial to consider other factors before making any investment decisions.

TG Therapeutics Inc. (TGTX) Sees Mixed Performance on January 19, 2024

TG Therapeutics Inc. (TGTX) experienced a mixed performance on January 19, 2024. The price of TGTX shares decreased by $0.07, marking a 0.46% drop from the previous market close. The stock closed at $15.07 but saw a slight increase of $0.03 in after-hours trading.

TGTX’s current trading position near the lower end of its 52-week range suggests that investors may perceive the stock as undervalued. However, it is important to note that the stock’s performance should be evaluated in conjunction with other fundamental and technical indicators to gain a comprehensive understanding of its investment potential.

Additionally, the fact that TGTX is trading below its 200-day simple moving average indicates a potential bearish sentiment in the market. When a stock is trading below this moving average, it suggests that the overall trend may be downward.

It is worth mentioning that the price change of $0.03 in after-hours trading may not have a significant impact on the overall performance of TGTX. After-hours trading refers to the buying and selling of stocks outside the regular trading hours of the stock market. The volume and liquidity during this period are typically lower compared to regular market hours, which can result in more volatile price movements.

Investors should closely monitor TGTX’s performance in the coming days to determine whether the recent price drop and subsequent after-hours increase are indicative of a trend reversal or merely short-term fluctuations. Conducting thorough research, considering the company’s financials, and consulting with a financial advisor can help investors make informed decisions regarding TGTX and their investment strategies.

TG Therapeutics Inc. (TGTX) Shows Mixed Performance with Significant Revenue Changes: A Path Towards Profitability

TG Therapeutics Inc. (TGTX) has shown mixed performance in its stock prices on January 19, 2024. The company’s total revenue has experienced significant changes over the past year and quarter. TGTX reported a total revenue of $2.79 million over the past year, representing a 58.36% decrease compared to the previous year. However, the company’s total revenue experienced a substantial 931.57% increase since the last quarter, reaching $165.81 million. TGTX reported a net loss of -$198.34 million over the past year, but the net income has increased by 43.02% compared to the previous year. In the third quarter of 2023, TGTX reported a net income of $113.93 million, indicating a remarkable 339.3% increase since the previous quarter. TGTX reported an EPS of -$1.46 over the past year, representing a loss per share. However, the company has improved its EPS by 44.37% compared to the previous year. In the third quarter of 2023, TGTX reported an EPS of $0.73, indicating a significant increase of 317.21% since the previous quarter. These positive trends suggest that TGTX has made significant strides in improving its financial performance and may be on a path towards profitability.

Tags: TGTX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Technology Robotics Trading online

Datasea Inc Implements Reverse Stock Split to Meet Nasdaq Listing Requirements

MMM stock news

Resumption of Trading for Arena Group Holdings Shares

Alternative Energy Markets and money (1)

Options Market Activity for Diamondback Energy Bullish vs Bearish Sentiment

Recommended

iRadimed Stock

iRadimed: Record Performance Meets Divergent Institutional Strategies

7 months ago
Alphabet Stock

Alphabet Shares Under Scrutiny as CEO Pichai Executes Multi-Million Dollar Stock Sale

6 months ago
Bloom Energy Stock

Bloom Energy Shares Plunge Following Spectacular Rally

4 months ago
Strategy Stock

Strategy Shares Plunge Following Dual Capital Raise Announcement

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Hesai Group’s Milestone Profit Tempered by Cautious Guidance

Trending

Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

by SiterGedge
March 25, 2026
0

As Humacyte prepares to release its full-year 2025 financial results, the biotechnology firm finds its stock trading...

Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026
Hain Celestial Stock

Hain Celestial Sheds Snack Division in Strategic Overhaul

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline
  • MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com